Skip to content

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section: A Prospective Randomized Double-Blinded Clinical Study

Status
Terminated
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03098420
Enrollment
29
Registered
2017-03-31
Start date
2016-07-31
Completion date
2021-05-20
Last updated
2021-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post Surgical Pain

Brief summary

The study aims to improve the care of the obstetric population after cesarean section and improve total patient satisfaction by improving post-surgical pain control with the use of dexamethasone in combination with bilateral TAP blocks. The investigators will utilize a dose-escalation of dexamethasone in the TAP block to observe its effects at specific small doses. It is the hope of the investigator that the studied technique would become utilized routinely for the obstetric population following cesarean section. The investigators hope to show that the addition of dexamethasone in bilateral TAP blocks will prolong the duration of the block in a dose-dependent fashion. The investigators hope to improve post-operative pain following cesarean section, increase duration of TAP block with use of dexamethasone, decrease overall pain scores in the first 24-48 hours, and decrease opioid requirements after cesarean section. The primary endpoint will be estimation of duration of TAP block, being assessed within 48 hours after surgery. Secondary endpoints will include pain scores both in PACU and on the floor, average pain scores, time until first opioid administration, total opioid consumption in first 48 hours, use of PONV medications, and overall patient satisfaction.

Detailed description

Preoperatively: informed consent will be obtained by a member of this study. The patients will be screened for inclusion/exclusion criteria on day of procedure, and then the participants will be randomized to one of three groups. Intraoperatively: The anesthesia team involved with care of patient in the operating room will provide routine anesthesia care during the cesarean section including neuraxial anesthesia with intrathecal bupivacaine and morphine. After completion of the procedure, the patients will receive bilateral TAP block procedure while still in OR. All blocks will include 20mL of 0.5% ropivacaine, and the patients will be randomly assigned a specific dose of dexamethasone at 0mg (given normal saline as control), 2mg, or 4mg. The resident or attending physician supervising the block will be investigators of the study, and they along with the residents performing the blocks will be blinded to the amount of dexamethasone in the injectate. Postoperatively: The patients will then be monitored in the PACU for approximately 30-60 minutes and then subsequently monitored on an inpatient floor. Pain scores, time until first opioid dose, total opioid requirement will be assessed and recorded. In PACU, these will be recorded every 15-30 minutes. On the inpatient floor, these will be recorded every 6 hours. Pain scores, average pain scores in first 48 hours, total opioid consumption, time until first opioid use, and PONV medication requirement will also be recorded. These will be recorded by review of the electronic medical record. Satisfaction scores and estimation of TAP block duration will be assessed and recorded by anesthesia personnel approximately 48 hours post-operatively; these will be subjective evaluations recorded between 24-38 hours postoperatively. The patients will be asked to estimate how long they felt the block lasted. For satisfaction scores, patients will rate their satisfaction subjectively on a scale of 1-10. Statistical Analysis: all demographic and clinical variables with continuous measures will be expressed as means and standard deviations; categorical factors will be expressed as proportions. For non-normal data, the medians and inter quartile ranges will be displayed. The distribution of the continuous factors will be examined using the Kolmogorov-Smirnov test. For data that are normally distributed, one-way ANOVA will be used to compare groups of data. For data that are not normally distributed, the Kruskal-Wallis test will be used for comparisons. Chi-square and Fisher's exact tests will be used to analyze categorical data. For all comparisons, a value of p \< 0.05 will be considered statistically significant. Statistical analyses will be performed using SAS for Windows, version 9.2. One-way ANOVA (or the Kruskal-Wallis test, as appropriate) will be used to compare duration of TAP block for the three groups. Linear regression will also be used to test the relationship between duration of block and dexamethasone dose, while controlling for relevant clinical and demographic variables. One-way ANOVA (or the Kruskal-Wallis test) will be used to compare the groups on post-operative pain scores, opioid requirements, and patient satisfaction scores. Statistical Power and Sample Size Estimates: Approximately 69 subjects (23 per group) are expected to be enrolled in this study. Given this sample size and assuming that the average duration of TAP block is 18 hours for the control group, 22 hours for the 2 mg of dexamethasone group, and 24 hours for the 4 mg of dexamethasone group, this study will have approximately 80.9% power to detect a difference in block duration, assuming a common standard deviation of 6 hours. If the variability in block time is smaller than 6 hours, this study will have greater power.

Interventions

DRUG2mg Dexamethasone

0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline

DRUG4mg Dexamethasone

1 mL (4mg) of dexamethasone

DRUGRopivacaine (TAP blocks)

20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine

DRUGMorphine
DRUGBupivacaine Hydrochloride
DRUGNormal saline 1ml

1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine

0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Masking description

The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate.

Intervention model description

Patients will be randomly assigned to 1 of 3 groups. They will be assigned to a group prior to being brought back to the operating room. The anesthesia team in the OR will take an envelope that has which group the patient will be randomly assigned to and they will perform the TAP block with the respective dose of dexamethasone. The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. Women undergoing cesarean section delivery. 2. Patients classified as American Society of Anesthesiology (ASA) class II or III. 1. ASA II: mild systemic disease, pregnancy 2. ASA III: severe systemic disease 3. Women ≥ 18 years old 4. Neuraxial anesthesia (spinal) to be used as anesthetic technique intraoperatively for cesarean section (this is the UAB Anesthesiology standard of care).

Exclusion criteria

1. Any patient not classified as an ASA I or II. 2. General Anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques for cesarean section. 3. Allergy/intolerance to local anesthetic or steroids. 4. Pre-existing neurological and/or anatomical deficit that would preclude regional block. 5. Coexisting coagulopathy such as hemophilia or von Willebrand Disease 6. BMI \> 40. 7. Emergency Cesarean Sections

Design outcomes

Primary

MeasureTime frameDescription
Average Pain Score48 hours postoperativelyAverage pain score (VAS) 48 hrs postoperatively between the study group and the control. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. 0 represents no pain, whereas 10 represents unbearable pain.

Secondary

MeasureTime frameDescription
First Post-Operative Opioid Administrationbaseline to 48 hrs postoperativelyTime until first dose post-operative opioid administration between the study group and the control
Average Opioid Consumptionfrom the time of delivery to 48hrs postoperativelyAverage opioid consumption 48 hrs postoperatively between the study group and the control

Countries

United States

Participant flow

Participants by arm

ArmCount
Control Group
20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine. Ropivacaine (TAP blocks): 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine Morphine Bupivacaine Hydrochloride Normal saline 1ml: 1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
7
2mg Dexamethasone
20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine. 2mg Dexamethasone: 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline Ropivacaine (TAP blocks): 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine Morphine Bupivacaine Hydrochloride Normal saline 0.5ml: 0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
9
4mg Dexamethasone
20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine. 4mg Dexamethasone: 1 mL (4mg) of dexamethasone Ropivacaine (TAP blocks): 20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine Morphine Bupivacaine Hydrochloride
13
Total29

Baseline characteristics

CharacteristicControl Group2mg Dexamethasone4mg DexamethasoneTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
7 Participants9 Participants13 Participants29 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
2 Participants5 Participants4 Participants11 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
4 Participants4 Participants9 Participants17 Participants
Sex: Female, Male
Female
7 Participants9 Participants13 Participants29 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 90 / 13
other
Total, other adverse events
0 / 70 / 90 / 13
serious
Total, serious adverse events
0 / 70 / 90 / 13

Outcome results

Primary

Average Pain Score

Average pain score (VAS) 48 hrs postoperatively between the study group and the control. The visual analog scale (VAS) is a validated, subjective measure for acute and chronic pain. 0 represents no pain, whereas 10 represents unbearable pain.

Time frame: 48 hours postoperatively

ArmMeasureValue (MEAN)Dispersion
Control GroupAverage Pain Score1.49 units on a scaleStandard Deviation 0.25
2mg DexamethasoneAverage Pain Score1.40 units on a scaleStandard Deviation 0.4
4mg DexamethasoneAverage Pain Score1.62 units on a scaleStandard Deviation 0.35
Secondary

Average Opioid Consumption

Average opioid consumption 48 hrs postoperatively between the study group and the control

Time frame: from the time of delivery to 48hrs postoperatively

ArmMeasureValue (MEAN)Dispersion
Control GroupAverage Opioid Consumption37.93 mg of morphine equivalentsStandard Deviation 13.5
2mg DexamethasoneAverage Opioid Consumption47.11 mg of morphine equivalentsStandard Deviation 12.44
4mg DexamethasoneAverage Opioid Consumption42.38 mg of morphine equivalentsStandard Deviation 9.17
Secondary

First Post-Operative Opioid Administration

Time until first dose post-operative opioid administration between the study group and the control

Time frame: baseline to 48 hrs postoperatively

ArmMeasureValue (MEAN)Dispersion
Control GroupFirst Post-Operative Opioid Administration22.43 HoursStandard Deviation 4.87
2mg DexamethasoneFirst Post-Operative Opioid Administration12.56 HoursStandard Deviation 3.58
4mg DexamethasoneFirst Post-Operative Opioid Administration18.25 HoursStandard Deviation 4.23

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026